78 related articles for article (PubMed ID: 27086600)
1. HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy.
Kawakami H; Yonesaka K
Recent Pat Anticancer Drug Discov; 2016; 11(3):267-74. PubMed ID: 27086600
[TBL] [Abstract][Full Text] [Related]
2. The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study.
Trinder A; Ding K; Zhang J
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38231075
[TBL] [Abstract][Full Text] [Related]
3. HER3 as a Therapeutic Target in Cancer.
Karachaliou N; Lazzari C; Verlicchi A; Sosa AE; Rosell R
BioDrugs; 2017 Feb; 31(1):63-73. PubMed ID: 28000159
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
Cleary JM; McRee AJ; Shapiro GI; Tolaney SM; O'Neil BH; Kearns JD; Mathews S; Nering R; MacBeath G; Czibere A; Sharma S; Korn WM
Invest New Drugs; 2017 Feb; 35(1):68-78. PubMed ID: 27853996
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
Liu JF; Ray-Coquard I; Selle F; Poveda AM; Cibula D; Hirte H; Hilpert F; Raspagliesi F; Gladieff L; Harter P; Siena S; Del Campo JM; Tabah-Fisch I; Pearlberg J; Moyo V; Riahi K; Nering R; Kubasek W; Adiwijaya B; Czibere A; Naumann RW; Coleman RL; Vergote I; MacBeath G; Pujade-Lauraine E
J Clin Oncol; 2016 Dec; 34(36):4345-4353. PubMed ID: 27998236
[TBL] [Abstract][Full Text] [Related]
6. Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.
Yonesaka K; Hirotani K; von Pawel J; Dediu M; Chen S; Copigneaux C; Nakagawa K
Lung Cancer; 2017 Mar; 105():1-6. PubMed ID: 28236978
[TBL] [Abstract][Full Text] [Related]
7. The prospect of patritumab for treating non-small cell lung cancer.
Horinouchi H
Expert Opin Biol Ther; 2016 Dec; 16(12):1549-1555. PubMed ID: 27744717
[TBL] [Abstract][Full Text] [Related]
8. HER3 signaling and targeted therapy in cancer.
Mishra R; Patel H; Alanazi S; Yuan L; Garrett JT
Oncol Rev; 2018 Jan; 12(1):355. PubMed ID: 30057690
[TBL] [Abstract][Full Text] [Related]
9. HER2 signaling regulates HER2 localization and membrane retention.
Jeong J; Kim W; Kim LK; VanHouten J; Wysolmerski JJ
PLoS One; 2017; 12(4):e0174849. PubMed ID: 28369073
[TBL] [Abstract][Full Text] [Related]
10. Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer.
Zhang S; Mukherjee S; Fan X; Salameh A; Mujoo K; Huang Z; Li L; To'a Salazar G; Zhang N; An Z
Oncotarget; 2016 Oct; 7(40):65758-65769. PubMed ID: 27582551
[TBL] [Abstract][Full Text] [Related]
11. Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance.
Sellappan S; Blackler A; Liao WL; O'Day E; Xu P; Thyparambil S; Cecchi F; Hembrough T; Catenacci DV
J Natl Compr Canc Netw; 2016 May; 14(5):503-7. PubMed ID: 27160229
[TBL] [Abstract][Full Text] [Related]
12. Insights into next developments in advanced gastric cancer.
Obermannová R; Lordick F
Curr Opin Oncol; 2016 Jul; 28(4):367-75. PubMed ID: 27092990
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
Jacob W; James I; Hasmann M; Weisser M
Cancer Treat Rev; 2018 Jul; 68():111-123. PubMed ID: 29944978
[TBL] [Abstract][Full Text] [Related]
14. Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
Lyu H; Han A; Polsdofer E; Liu S; Liu B
Acta Pharm Sin B; 2018 Jul; 8(4):503-510. PubMed ID: 30109175
[TBL] [Abstract][Full Text] [Related]
15. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
[TBL] [Abstract][Full Text] [Related]
16. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
17. U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer.
Koganemaru S; Kuboki Y; Koga Y; Kojima T; Yamauchi M; Maeda N; Kagari T; Hirotani K; Yasunaga M; Matsumura Y; Doi T
Mol Cancer Ther; 2019 Nov; 18(11):2043-2050. PubMed ID: 31395690
[TBL] [Abstract][Full Text] [Related]
18. Development of Effective Therapeutics Targeting HER3 for Cancer Treatment.
Liu X; Liu S; Lyu H; Riker AI; Zhang Y; Liu B
Biol Proced Online; 2019; 21():5. PubMed ID: 30930695
[TBL] [Abstract][Full Text] [Related]
19. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
